As always thanks for your research and post. Isn’t the 47 example a deterrent to jumping the gun for an M&A unless the acquirers are afraid that if they go thru the full phase 2/3 and the drug is both safe and effective then they wouldn’t have to multiples of current valuation?
Given that in Bis’ case we have wider applications and hence higher potential, also we have safety data from historical trials and AML but how tempted could BP for a deal at 1b stage I am hoping to know in the next 12 months.
As always thanks for your research and post. Isn’t the 47...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
